Differential expression of cytokines in breast cancer patients receiving different chemotherapies: implications for cognitive impairment research
Differential expression of cytokines in breast cancer patients receiving different chemotherapies: implications for cognitive impairment research
复制标题
DOI：
10.1007/s00520-011-1158-0
复制
发表时间：
2012-04-01
影响因子：
3.1
通讯作者：
Morrow, Gary R.
中科院分区：
文献类型：
--
作者：
Janelsins, Michelle C.;Mustian, Karen M.;Morrow, Gary R.
细胞因子和趋化因子水平的改变可能在癌症和癌症治疗相关的认知困难中发挥作用。在许多神经退行性疾病中，细胞因子和趋化因子浓度异常会影响神经元完整性，导致认知障碍，但细胞因子在癌症患者化疗相关认知困难中的作用尚不清楚。接受基于阿霉素（环磷酰胺或环磷酰胺加氟尿嘧啶；AC/CAF）化疗或环磷酰胺、甲氨蝶呤和氟尿嘧啶（CMF）化疗的患者报告出现认知困难；由于这些方案通过不同的作用方式起作用，因此它们可能对细胞因子水平产生不同的影响。本研究在 54 名接受 AC/CAF 或 CMF 的早期乳腺癌患者中检查了细胞因子水平（即 IL-6、IL-8 和 MCP-1）与化疗类型之间的关系。在两个时间点评估细胞因子水平：在研究化疗周期 2 之前（周期 2）和两个连续化疗周期之后（在研究周期 4 之前；周期 4）。使用周期 2 水平作为协变量的方差分析 (ANCOVA) 用于确定化疗组之间的差异。 AC/CAF组IL-6、IL-8和MCP-1水平升高，CMF组降低；唯一显着的组间变化是 IL-6（p < 0.05）。这些结果虽然是基于小样本量的初步结果，但表明 AC/CAF 化疗比 CMF 更能诱导细胞因子。未来的研究应该证实这些结果，并在评估癌症患者的认知功能时探索不同化疗方案引起的不同炎症反应。
Altered levels of cytokines and chemokines may play a role in cancer- and cancer treatment-related cognitive difficulties. In many neurodegenerative diseases, abnormal concentrations of cytokines and chemokines affect neuronal integrity leading to cognitive impairments, but the role of cytokines in chemotherapy-related cognitive difficulties in cancer patients is not well understood. Patients receiving doxorubicin-based (with cyclophosphamide, or cyclophosphamide plus fluorouracil; AC/CAF) chemotherapy or cyclophosphamide, methotrexate, and fluorouracil (CMF) chemotherapy report experiencing cognitive difficulties; because these regimens work by different modes of action, it is possible that they differentially affect cytokine levels.This study examined the relationships between cytokine levels (i.e., IL-6, IL-8, and MCP-1) and type of chemotherapy among 54 early-stage breast cancer patients receiving AC/CAF or CMF. Cytokine levels were assessed at two time-points: prior to on-study chemotherapy cycle 2 (cycle 2) and after two consecutive chemotherapy cycles (prior to on-study cycle 4; cycle 4).Analyses of variance using cycle 2 levels as a covariate (ANCOVA) were used to determine differences between chemotherapy groups. Levels of IL-6, IL-8, and MCP-1 increased in the AC/CAF group and decreased in the CMF group; the only significant between-group change was in IL-6 (p < 0.05).These results, although preliminary based on the small sample size, suggest that AC/CAF chemotherapy is more cytokine inducing than CMF. Future studies should confirm these results and explore the distinct inflammatory responses elicited by different chemotherapy regimens when assessing cognitive function in cancer patients.